Wed May 04 2022

NEW STUDY

Circulating suPAR associates with severity and in-hospital progression of COVID-19

BACKGROUND:
COVID-19 disease progression is characterized by hyper inflammation, and risk stratification may aid in early aggressive treatment and advanced planning. The aim of this study was to assess if suPAR and other markers measured at hospital admission can predict the severity of COVID-19.

METHODS:
Circulating suPAR associates with severity and in-hospital progression of COVID-19The primary outcome measure in this international, multi-center, prospective, observational study with adult patients hospitalised primarily for COVID-19 was the association of the World Health Organization Clinical Progression Scale (WHO-CPS) with suPAR ferritin, CRP, albumin, LDH, eGFR, age, procalcitonin, and interleukin-6. Admission plasma suPAR levels were determined using the suPARnostic® ELISA and suPARnostic® Turbilatex assays.

RESULTS:
767 patients, 440 (57.4%) males, and 327 (42.6%) females were included, with mean age of 62 years. Log-suPAR levels were significantly correlated with WHO-CPS score, with every doubling of suPAR increasing the score by one point (p<0.001). All the other markers were also significantly associated with the WHO-CPS score. Admission suPAR levels were significantly lower in survivors (7.10 vs. 9.63, 95% CI 1.47-3.59, p<0.001). A linear model (SALGA) including suPAR, serum albumin, serum lactate dehydrogenase, eGFR, and age can best estimate the WHO-CPS score and survival. Combining all five parameters in the SALGA model can improve the accuracy of discrimination with an AUC of 0.80 (95% CI: 0.759-0.836).

CONCLUSIONS:
suPAR levels were significantly correlated with WHO-CPS score, with every doubling of suPAR increasing the score by one point. The SALGA model may serve as a quick tool at admission for predicting disease severity and survival.

900+

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 3 products:

Quick Triage

A Point of Care Solution

TurbiLatex

For Automated Systems

ELISA Assay

Clinical and Research

suPAR is used in clinical routine in 48 hospitals

48 hospitals use suPAR in clinical routine for triage of patients in the Emergency Departments and COVID-19 units. Clinical routine is defined by the placement of two Purchasing Orders within the last 12 months rolling.
This period covers January 1, 2022, until December 31, 2022. Some hospital locations cannot be disclosed due to confidentiality.

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates